Want to see AU:ENP full AI Analyst Report?
Top Page
Tryptamine Therapeutics
(Sydney:ENP)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.03
â–Ľ(-27.50% Downside)
Action:Reiterated
Date:10/19/26
The score is held down primarily by weak financial performance driven by a lack of revenue and ongoing losses with continued cash burn, despite some improvement in 2026. Technicals are neutral-to-soft (below short-term averages and slightly negative MACD), and valuation is difficult to support given negative earnings and no dividend data.
Positive Factors
Debt-free balance sheet
Positive equity and no reported debt through 2026 give the company a comparatively resilient financial base, reducing interest and refinancing pressure while it advances development. This preserves flexibility to direct capital toward its programs over the next several quarters.
Negative Factors
No established revenue base
Revenue was zero in 2026, 2025, 2024 and 2021, and the pack describes minimal to no recurring revenue. Without commercial sales, the company lacks an established operating engine, leaving future funding needs closely tied to development progress rather than internally generated income.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Positive equity and no reported debt through 2026 give the company a comparatively resilient financial base, reducing interest and refinancing pressure while it advances development. This preserves flexibility to direct capital toward its programs over the next several quarters.
Read all positive factors
Tryptamine Therapeutics (ENP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$49.03M
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue GrowthN/A
EPS Growth29.55%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,634,217,200
10 Day Avg. Volume1,296,304
30 Day Avg. Volume1,299,503
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)6.82
Price to Sales (P/S)0.00
P/FCF Ratio-14.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Tryptamine Therapeutics Business Overview & Revenue Model
Company Description
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical co...
Tryptamine Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Aug 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 618.57K | 99.73K |
| Gross Profit | -27.34K | -54.34K | -6.77K | 618.57K | 99.73K |
| EBITDA | -6.74M | -5.27M | -6.70M | -5.10M | -8.27M |
| Net Income | -4.87M | -5.33M | -6.14M | -7.13M | -10.08M |
Balance Sheet | |||||
| Total Assets | 8.38M | 6.66M | 7.45M | 5.88M | 13.61M |
| Cash, Cash Equivalents and Short-Term Investments | 5.58M | 3.03M | 5.37M | 1.64M | 4.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.53M | 3.74M |
| Total Liabilities | 1.02M | 699.17K | 1.83M | 1.75M | 4.81M |
| Stockholders Equity | 7.36M | 5.96M | 5.62M | 4.13M | 8.81M |
Cash Flow | |||||
| Free Cash Flow | -3.41M | -7.90M | -6.00M | -4.03M | -9.72M |
| Operating Cash Flow | -3.41M | -7.77M | -6.00M | -4.03M | -8.59M |
| Investing Cash Flow | -10.41K | -133.40K | 1.68M | -9.08K | -1.24M |
| Financing Cash Flow | 5.97M | 5.60M | 9.27M | 2.39M | 1.95M |
Tryptamine Therapeutics Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.03
Negative
Market Momentum
>-0.01
Positive
32.71
Neutral
32.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ENP, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.71 is Neutral, neither overbought nor oversold. The STOCH value of 32.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ENP.
Tryptamine Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.40B | 125.71 | 6.03% | 0.79% | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$154.97M | -8.75 | -103.42% | ― | ― | 5.88% | |
43 Neutral | AU$49.03M | -13.04 | -63.60% | ― | ― | 29.55% | |
42 Neutral | AU$21.04M | -3.88 | -30.02% | ― | ― | -10.32% | |
41 Neutral | AU$42.60M | -5.15 | -18.71% | ― | ― | 21.23% |
* Healthcare Sector Average
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-18.92%
AU:ATX
Amplia Therapeutics
0.08
-0.04
-33.60%
AU:ACW
Actinogen Medical
0.04
<0.01
21.21%
AU:NEU
Neuren Pharmaceuticals Limited
18.95
-2.35
-11.05%
AU:ZLD
Zelira Therapeutics
0.50
0.17
51.52%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.05
-0.07
-55.00%
Tryptamine Therapeutics Corporate Events
Entropy Neurodynamics Boosts Director Equity Through Share-Based Fees
Oct 14, 2026
Entropy Neurodynamics Limited has disclosed a change in director Herwig Janssen’s interests, with the issuance of 623,441 ordinary fully paid shares in lieu of cash fees for services rendered between July and September 2026. This equity-base...
Entropy Neurodynamics Issues Director Fee Shares, Confirms Regulatory Compliance
Oct 14, 2026
Entropy Neurodynamics Limited has issued 623,441 fully paid ordinary shares to its directors in lieu of cash payment of directors’ fees, as previously approved at its 13 November 2025 Annual General Meeting. The company has lodged the associ...
Entropy Neurodynamics Issues Equity to Directors in Lieu of Cash Fees
Oct 14, 2026
Entropy Neurodynamics Limited, an ASX-listed company in the neurotechnology and neuroscience domain, structures director remuneration so that fees may be paid in shares rather than cash. The use of ordinary fully paid shares for board compensation...
Entropy Neurodynamics posts 2026 AGM materials and streamlines investor communications
Oct 4, 2026
Entropy Neurodynamics Limited has released key documents for its 2026 Annual General Meeting, including the notice of meeting, a letter of access and proxy form, signalling the next formal step in its governance calendar as a recently listed clini...
Entropy Neurodynamics Sets Date for 2026 AGM and Director Nomination Deadline
Sep 14, 2026
Entropy Neurodynamics Limited has scheduled its 2026 Annual General Meeting for 12 November 2026 at 4:00pm AEDT in Hawthorn East, Victoria, and has set 24 September 2026 as the closing date for director nominations. The company is also encouraging...
Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803
Sep 13, 2026
Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing precision-controlled psychedelic therapies, led by its IV-infused psilocin candidate TRP-8803 for treatment-resistant binge eating disorder. The company is buildin...
Entropy Neurodynamics to Showcase Psilocin Program in Investor Webinar
Aug 28, 2026
Entropy Neurodynamics Limited, a clinical-stage biotech focused on psilocin-based psychedelic-assisted therapies, is advancing proprietary formulations aimed at treating conditions with unmet medical needs. Its lead candidate, TRP-8803, delivers p...
Entropy Neurodynamics Files ASX Governance Disclosures for 2026
Aug 28, 2026
Entropy Neurodynamics Limited has lodged its Appendix 4G and corporate governance statement with the ASX for the financial year ended 30 June 2026, confirming board approval and compliance with the exchange’s disclosure framework. The compan...
Entropy Neurodynamics Narrows Annual Loss as Revenue Jumps 30%
Aug 28, 2026
Entropy Neurodynamics Limited operates in the neurodynamics and therapeutics sector, with related entities Tryp Therapeutics Inc in Canada and Tryp Therapeutics (USA) Inc in the U.S. preparing their accounts under IFRS Accounting Standards. The gr...
Entropy Neurodynamics Plans U.S. Phase 2 Trial Pitting Psychedelic Therapy Against Lexapro
Aug 26, 2026
Entropy Neurodynamics has signed a pre-Clinical Trial Agreement with the University of California, San Francisco to run a U.S. Phase 2 trial comparing its IV psilocin candidate TRP-8803 against escitalopram in up to 80 young adults with Major Depr...
Entropy Neurodynamics Seeks ASX Quotation for 1 Million New Shares
Aug 24, 2026
Entropy Neurodynamics Limited has lodged a new application with the ASX for the quotation of 1,000,000 ordinary fully paid shares under its existing ENP code, with an issue date of August 21, 2026. The move formalizes the listing of these addition...
Entropy Neurodynamics Seeks Trading Halt Ahead of Key U.S. Phase 2 Trial Update
Aug 24, 2026
Entropy Neurodynamics has requested a trading halt on its ordinary shares from the start of ASX trading on 24 August 2026, with the halt to remain in place until either 26 August 2026 or the release of a pending announcement. The move signals a fo...
Entropy Neurodynamics secures BioCina for global-scale manufacturing of IV psilocin therapy
Aug 18, 2026
Entropy Neurodynamics has signed a Development and Manufacturing Services Agreement with BioCina to produce its proprietary TRP-8803 intravenous psilocin formulation under GMP conditions. The deal secures access to BioCina’s TGA-licensed, FD...
Entropy Neurodynamics Boosts Director Equity Through Share-Based Fees
Aug 7, 2026
Entropy Neurodynamics Limited has disclosed a change in director Herwig Janssen’s holdings, reflecting the issuance of additional ordinary fully paid shares. The update was lodged under Australian Securities Exchange requirements, detailing ...
Entropy Neurodynamics Issues Director Fee Shares, Confirms Regulatory Compliance
Aug 7, 2026
Entropy Neurodynamics has issued 766,871 fully paid ordinary shares to directors in lieu of cash fees, as previously approved at its November 2025 annual general meeting, and has lodged the relevant Appendix 2A with the ASX. The company confirmed ...
Entropy Neurodynamics Issues New Shares in Lieu of Directors’ Fees
Aug 7, 2026
Entropy Neurodynamics Limited has applied to the ASX for quotation of 766,871 ordinary fully paid shares, to be issued on August 7, 2026. These shares are being issued in lieu of cash payment for directors’ fees, following prior approval by ...
Tryp Therapeutics Showcases World-First Binge Eating Trial in Psychedelic Neuropsychiatry
Aug 6, 2026
Tryp Therapeutics, presented under the Entropy Neurodynamics banner at the Bioshares 2026 Investor Roadshow, is highlighting world-first clinical results in treating resistant binge eating disorder using psychedelic-assisted approaches. The compan...
Entropy Neurodynamics wins approval for multi-indication TRP-8803 basket trial
Aug 3, 2026
Entropy Neurodynamics has secured Human Research Ethics Committee approval and a Clinical Trial Research Agreement with Swinburne University for a Phase 1b/2a basket trial of its IV-infused psilocin therapy TRP-8803 in 72 patients. The world-first...
Entropy Neurodynamics Halts Trading Ahead of Key Ethics Approval Update
Jul 31, 2026
Entropy Neurodynamics Ltd (ASX: ENP) has requested a trading halt on its ordinary shares from the start of trading on 31 July 2026 until the earlier of the market open on 4 August 2026 or the release of a pending announcement. The halt has been im...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.